Article Text

other Versions

Download PDFPDF
Review
Endovascular thrombectomy after acute ischemic stroke of the basilar artery: a meta-analysis of four randomized controlled trials
  1. Gautam Adusumilli1,
  2. Hassan Kobeissi2,
  3. Sherief Ghozy2,
  4. Nicole Hardy3,
  5. Kevin M Kallmes3,
  6. Kristen Hutchison3,
  7. David F Kallmes2,
  8. Waleed Brinjikji2,
  9. Gregory W Albers4,
  10. Jeremy J Heit5
  1. 1Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA
  2. 2Department of Radiology, Mayo Clinic Minnesota, Rochester, Minnesota, USA
  3. 3Nested Knowledge Inc, Saint Paul, Minnesota, USA
  4. 4Department of Neurology, Stanford University, Stanford, California, USA
  5. 5Department of Radiology, Neuroradiology and Neurointervention Division, Stanford University, Stanford, California, USA
  1. Correspondence to Dr Jeremy J Heit, Department of Radiology, Neuroradiology and Neurointervention Division, Stanford University, Stanford, California, USA; jheit{at}stanford.edu

Abstract

Background Previous randomized controlled trials (RCTs) and meta-analyses were underpowered to demonstrate the superiority of endovascular thrombectomy (EVT) over medical therapy (MEDT) in the treatment of acute ischemic stroke due to large vessel occlusion of the posterior circulation (PC-LVO). We performed an updated systematic review and meta-analysis after the publication of the BAOCHE and ATTENTION trials to determine whether EVT can benefit patients presenting with PC-LVO.

Methods Using Nested Knowledge, we screened literature for RCTs on EVT in PC-LVO. The primary outcome was 90-day modified Rankin Scale (mRS) score 0–3, and secondary outcomes included 90-day mRS score 0–2, 90-day mortality, and rate of symptomatic intracranial hemorrhage (sICH). A random-effects model was used to compute rate ratios (RRs) and their corresponding 95% confidence intervals (CIs).

Results Four RCTs with 988 patients, 556 patients in the EVT arm and 432 patients in the MEDT arm, were included in the meta-analysis. EVT resulted in significantly higher rates of mRS score 0–3 (RR=1.54; 95% CI 1.16 to 2.04; P=0.002) and functional independence (RR=1.83; 95% CI 1.08 to 3.08; P=0.024), and lower rates of mortality (RR=0.76; 95% CI 0.65 to 0.90; P=0.002) at 90-day follow-up compared with MEDT alone. However, EVT patients had higher rates of sICH (RR=7.48; 95% CI 2.27 to 24.61; P<0.001).

Conclusions EVT conferred significant patient benefit over MEDT alone in the treatment of PC-LVO. Future studies should better define patients for whom EVT is futile and determine factors that contribute to higher rates of sICH.

  • Stroke
  • Thrombectomy
  • Thrombolysis
  • Posterior fossa
  • Intervention

Data availability statement

Data are available upon reasonable request. All data are available within an extracted database on Nested Knowledge and can be shared upon reasonable request, as this is a meta-analysis compiling data from already published randomized controlled trials.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available upon reasonable request. All data are available within an extracted database on Nested Knowledge and can be shared upon reasonable request, as this is a meta-analysis compiling data from already published randomized controlled trials.

View Full Text

Footnotes

  • Twitter @MDDarkKnight, @JeremyHeitMDPHD

  • Contributors GA made substantial contributions to the conception and design of the work, the acquisition, analysis, and interpretation of data for the work, drafted the work, and gave final approval of the version to the published. HK made substantial contributions to the acquisition and interpretation of data for the work, revised it critically for important intellectual content, and gave final approval of the version to the published. SG made substantial contributions to the analysis and interpretation of data for the work, revised it critically for important intellectual content, and gave final approval of the version to the published. NH made substantial contributions to the acquisition of data for the work, revised it critically for important intellectual content, and gave final approval of the version to the published. KMK made substantial contributions to the conception and design of the work, revised it critically for important intellectual content, and gave final approval of the version to the published. KH made substantial contributions to the acquisition of data for the work, revised it critically for important intellectual content, and gave final approval of the version to the published. DFK made substantial contributions to the conception and design of the work, revised it critically for important intellectual content, and gave final approval of the version to the published. WB made substantial contributions to the conception and design of the work, revised it critically for important intellectual content, and gave final approval of the version to the published. GWA made substantial contributions to the conception and design of the work, revised it critically for important intellectual content, and gave final approval of the version to the published. JJH made substantial contributions to the conception and design of the work, the interpretation of data for the work, drafted the work, revised it critically for important intellectual content, and gave final approval of the version to the published. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. JH is the guarantor of the entire study.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests JJH is a consultant for Medtronic and MicroVention, a member of the medical and scientific advisory board for iSchemaView, and a member of the JNIS Editorial Board as a Member-at-Large in Neuroradiology. GWA is a consultant for Genentech and iSchemaView and holds equity in iSchemaView. DFK holds equity in Nested Knowledge, Superior Medical Editors, and Conway Medical, Marblehead Medical and Piraeus Medical; receives grant support from MicroVention, Medtronic, Balt, and Insera Therapeutics; has served on the Data Safety Monitoring Board for Vesalio; and received royalties from Medtronic. WB has compensation for consultant services from Johnson & Johnson, Stryker, Medtronic Vascular and Microvention; compensation from MIVI Neurovascular for data and safety monitoring services; stock holdings from Marblehead Medical LLC. KH works for Nested Knowledge, Inc. KMK works for, and holds equity in, Nested Knowledge, Inc., works for Conway Medical LLC, and holds equity in Superior Medical Experts, Inc. NH works for and holds equity in Nested Knowledge, Inc.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.